Jan 13 2010
Spectros announced today that the T-Stat® Tissue Oximeter sensor line will be expanded to include the new Continuum™ Cerebral Sensor line upon receipt of FDA marketing approval anticipated in 2010.
The T-Stat continuum sensor relies on broadband, multispectral visible and infrared illumination in order to obtain market-leading absolute tissue oximetry noninvasively in tissues such as the brain, gut, and breast. An FDA review process for marketing approval is underway, and Spectros anticipates marketing the Continuum sensor upon receipt of FDA marketing approval. Clinical studies of the Continuum sensor were initiated in 2008, with additional studies planned and in progress.
"The expansion of the T-Stat product line to include cerebral sensors furthers the already market-leading accuracy and success of the T-Stat into cerebral oximetry monitoring," notes Elizabeth van Thillo, Director of Marketing. "We currently have additional clinical studies at multiple clinical centers and will continue to demonstrate the efficacy of the T-Stat with the Continuum sensor line to reduce hospitalization costs and improve patient outcome in high-risk populations with early diagnosis."